New study shows benefits of Gla-300 treatment for patients with type 2 diabetes

In data presented as a late-breaking poster at the 2021 American Diabetes Association Virtual Meeting, Eugene Wright, MD, and the team studied people with type 2 diabetes (T2DM) who switched from basal insulin (IB) to second-generation (2nd generation) IB, Gla-300, or first-generation IB (Gla-100, IDet) during their treatment.

The change in insulin treatment in participants was recorded between April 1, 2015 and August 31, 2019. The team noted that patients with type 2 diabetes may change BI treatment for clinical, personal reasons. and financial. Form changes are also common.

There were 3,077 participants in each cohort, with an average age of 68 years. About half of the participant group were female, and data on each participant was collected using the Optum Clinformatics claims database.

Participants were followed for 12 months or until planned de-enrollment or death. The cohorts were matched by propensity score (PSM) on baseline demographic / clinical characteristics, and the outcomes assessed during the study were persistence (days of uninterrupted treatment), adherence (proportion of days covered), health resource use and costs.

Investigators found that participants with T2DM who switched to Gla-300 showed greater persistence and adherence to treatment than those who switched to 1st generation IB. A change in A1C from baseline at 12 months was also significantly greater in participants who switched to Gla-300.

Additionally, while participants who switched to Gla-300 had significantly higher pharmacy costs, they also had lower all-cause hospitalization costs and hypoglycemia-related emergency costs. In general, lower total health costs were recorded in Gla-300 patients.

Total healthcare costs for participants who switched to Gla-300 were $ 41,255 (of which $ 22,613 was related to diabetes), while total healthcare costs for participants who switched to BI 1st generation were $ 45,316 (of which $ 25,165 was related to diabetes).

In addition, persistence and adherence in the first group was also recorded to be higher than that of 1st generation BI participants. Persistence and adherence were recorded at 45.5% and 42.8% for Gla-300 participants, and 42.1% and 38.2% for 1st generation participants.

“Switching to Gla-300 has been associated with lower persistence, adherence and, despite these associated costs, lower health resource use than switching to 1st generation BI, in people with T2D previously treated with BI therapy, ”the team wrote. “This is the first study to assess these results in tandem. “

Wright and his colleagues are leading the charge in the study of diabetes and its management. As they noted in the study, patients may switch to different insulin treatments for a variety of reasons.

However, their study shows that while Gla-300 patients may have higher pharmacy costs, their overall healthcare costs were significantly lower, while their overall commitment to diabetes treatment was significantly higher.

The study, “Persistence, adherence, health care resource use and real world costs I, people with type 2 diabetes (T2D) switching from basal insulin (IB) to second generation IB (insulin glargine 300) U / mL [Gla-300]) vs 1st generation BI (Insulin Glargine 1) “, was published online by ADA.

About John Tuttle

Check Also

Quit vaping programs are becoming essential for today’s workers

Vaping has become a growing concern in the workplace, with nearly 11 million American adults …

Leave a Reply

Your email address will not be published.